Clinical Trial Search

Primary: Change in Craving on the Alcohol Urge Questionnaire (AUQ) After Administration of Oxytocin vs. Placebo During the 3-week Study. — 1.11; 0.69 units on a 7-pt Likert Scale

Primary: Percentage of Participants With Sustained Virological Response Rate in Relation to Interleukin 28B Expression — 63.2; 26.4; 33.3 Percentage of participants — p=0.0007

Primary: Difference in CD4+ T Cell Percentage Between Week 0 and Week 48 — -10.08 percentage of CD4+ T cells — p=<0.0001

Primary: Number of Participants With Human Anti-Human Antibodies (HAHAs) — 0; 0 participants

Primary: Number of Treatment Emergent (Serious and Non-serious) Adverse Events — 100; 2; 98 number of events

Primary: Efficacy (as Measured by Objective Response Rate) of Akt Inhibitor MK2206 in Patients With Recurrent High-grade Platinum-resistant Serous Ovarian, Fallopian Tube, or…

Primary: Accurate Vesical PRessure — 18.56; 17.45 cm H2O

Primary: Number of Participants With Any Adverse Events (AEs), Serious Adverse Events (SAEs), AEs of Grades 3/4, and Death — 26; 10; 21; 3 participants

Primary: Rate of Appearance of 3H Cholesterol in the Total HDL Fraction Before and After 12 Weeks of Treatment With Niacin — 3.24; 4.16; 2.61; 3.72 %/mol/h — p=0.8

Primary: Excess Body Weight Loss After RFA Treatment — 28.36 percentage of EBWL

Primary: Physical Global Assessment — 12; 0; 9; 20 participants — p=<0.05

Primary: Safety - Adverse Event Rate and Severity — 100; 100; 100; 33.3 percentage of participants and severity

Primary: Thoracopulmonary Compliance — 51.9; 52.3; 34.6; 31.9 ml/cmH2O

Primary: Amount of Time to Complete Assessment and Plan — 8.5; 8.7 minutes — p=0.047

Primary: Overall Survival (OS) in Participants Who Received at Least One Dose of Blinded Study Therapy at Primary Endpoint — 13.37; 12.42 months — p=0.2517